Evidence map›Paper›PMID 38726205›Full record

ReviewHeliyon2024

The Intersection of cerebral cholesterol metabolism and Alzheimer's disease: Mechanisms and therapeutic prospects.

Li-Cheng Liu, Jun-Yi Liang, Yan-Hong Liu, Bin Liu, Xiao-Hong Dong, Wen-Hui Cai, Ning Zhang

RetractedAbstract readReview
In one paragraph

Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

  • Retraction · 2025-07-16Computer-Aided Content or Computer-Generated Content · Concerns/Issues about Peer Review · Concerns/Issues about Referencing/Attributions · Investigation by Journal/Publisher · Objections by Author(s) · Unreliable Results and/or Conclusions ·
5 · Who and what money

Authors and funding

7 authors.

Li-Cheng LiuPharmaceutical Branch, Harbin Pharmaceutical Group Co., Harbin, Heilongjiang Province, China.
Jun-Yi LiangHeilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province, China.
Yan-Hong LiuHeilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province, China.
Bin LiuHeilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province, China.
Xiao-Hong DongJiamusi College, Heilongjiang University of Traditional Chinese Medicine, Jiamusi, Heilongjiang Province, China.
Wen-Hui CaiHeilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province, China.
Ning ZhangHeilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a common neurodegenerative disease in the elderly, the exact pathogenesis of which remains incompletely understood, and effective preventive and therapeutic drugs are currently lacking. Cholesterol plays a vital role in cell membrane formation and neurotransmitter synthesis, and its abnormal metabolism is associated with the onset of AD. With the continuous advancement of imaging techniques and molecular biology methods, researchers can more accurately explore the relationship between cholesterol metabolism and AD. Elevated cholesterol levels may lead to vascular dysfunction, thereby affecting neuronal function. Additionally, abnormal cholesterol metabolism may affect the metabolism of β-amyloid protein, thereby promoting the onset of AD. Brain cholesterol levels are regulated by multiple factors. This review aims to deepen the understanding of the subtle relationship between cholesterol homeostasis and AD, and to introduce the latest advances in cholesterol-regulating AD treatment strategies, thereby inspiring readers to contemplate deeply on this complex relationship. Although there are still many unresolved important issues regarding the risk of brain cholesterol and AD, and some studies may have opposite conclusions, further research is needed to enrich our understanding. However, these findings are expected to deepen our understanding of the pathogenesis of AD and provide important insights for the future development of AD treatment strategies targeting brain cholesterol homeostasis.

Indexed as

Alzheimer's diseaseAmyloid β proteinBrain cholesterolCholesterol homeostasisCholesterol metabolismTherapeutic pathway

Identifiers

PMID38726205
PMCPMC11079309

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.